TW211520B - - Google Patents
Download PDFInfo
- Publication number
- TW211520B TW211520B TW081104618A TW81104618A TW211520B TW 211520 B TW211520 B TW 211520B TW 081104618 A TW081104618 A TW 081104618A TW 81104618 A TW81104618 A TW 81104618A TW 211520 B TW211520 B TW 211520B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- concentration
- patent application
- item
- weight
- Prior art date
Links
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims abstract description 39
- 229960004296 megestrol acetate Drugs 0.000 claims abstract description 37
- 239000000725 suspension Substances 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 12
- 229920000136 polysorbate Polymers 0.000 claims abstract description 11
- 229950008882 polysorbate Drugs 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000000872 buffer Substances 0.000 claims abstract description 4
- 239000000796 flavoring agent Substances 0.000 claims abstract description 4
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 4
- 239000003765 sweetening agent Substances 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- -1 polyethylene Polymers 0.000 claims description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000005189 flocculation Methods 0.000 claims description 5
- 230000016615 flocculation Effects 0.000 claims description 4
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000000196 tragacanth Substances 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 229940116362 tragacanth Drugs 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229960001786 megestrol Drugs 0.000 claims description 2
- 229940100474 polyethylene glycol 1450 Drugs 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 239000004698 Polyethylene Substances 0.000 claims 3
- 229920000573 polyethylene Polymers 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000009434 installation Methods 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BKWJSCFKITXBBM-NTNOATJHSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-10,13-dimethyl-6-methylidene-2,7,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C(=C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 BKWJSCFKITXBBM-NTNOATJHSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229940026692 decadron Drugs 0.000 description 1
- 229940063223 depo-provera Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Description
Λ6 F56 211520 五、發明説明(1 ) (請先閲讀背面之注意事項再填寫本頁) 本案係為07/839, 016之CIP,其係為 07/7 1 7 1 55 (現在已改案)之連缠案。 本發明偽關於包含甲地孕酮乙酸酯之藥學組成物。甲 地孕酬乙酸酯係為1 7 — α —醛氣基一6 —甲基娠一 4, 6 —二締一 3, 2 0—二_ 之俗名,其偽由 Bristol-Mye- rs Squibb Corporation以Megace之專利名稱出售的抗一 赘瘤藥物。
Kirk,et al,U.S·專利3356573號掲示包含 乳糖、硬脂酸鎂及澱粉之甲地孕酮乙酸酯藥片製劑。!^!·-k,et al,亦論及甲地孕酮乙酸酯之液體組成物可為溶液 、乳液、懸浮液、漿體及酊劑形態,但未詳細述及此等組 成物之組成。 ?41*〇«,4&1,11.3.專利4,396,6 1 5號掲 示同時投服6 —亞甲基孕甾酮.衍生物與甲地孕酮乙酸酯以 治療和男性激素相關之疾病的方法,但未詳細述及甲地孕 酮乙酸酯組成物之構成成份。 經濟部中央標中局貝工消費合作社印製 6“&1163?,61&1.,11.8.專利4,3 7 0,3 2 1號 掲示使用甲地孕酮乙酸酯治療乳癌之佐助治療。未詳細說 明甲地孕酮乙酸酯組成物之種類或組成。 1^1?1'16,1].5.專利4 6 6 6 8 8 5號掲示女性乳癌之 綜合治療,其包括投服黃體化激素以及抗一男性素(諸如 甲地孕酮乙酸酯)。尤其是,在第8欄,58—61行上 之-8 5 5病人掲示抗男性素和傳統藥學佐劑(例如,噴 霧乾燥乳糖和硬脂酸鎂)調製成口服用Μ劑或膠囊。 本纸張尺度適用中a國家桴苹(CNS) V 4規格(210 X 297公楚)一3 — 2115^0 A6 B6 經濟部中央標準局員工消費合作杜印製 五、發明説明(2 ) Labr i e . U · S .專利4 7 6 0 0 5 3號傜關於和性別類 固醇相關之癌症的治療,其包括使用甲地孕酮,但未述及 治療中所用藥學組成物之種類或組成 。 Labi* ie,U.S·專利4 7 7 5 6 6 1號係關於女性乳癌 之結合治療,其中係掲示甲地孕酮作為適當之類固醇性抗 男性素。此外,還掲示甲地孕酮乙酸酯(活性成份)與結 合劑(諸如聚乙二醇)混合且可包含口味改良物質(其可 製成Η劑或錠劑核心)。 J· H. Von Roenn,et al, Annals of Internal Medicine, 109, 840-841(1988)掲示使用甲地孕酮乙酸酯治 療惡病質以及人類免疫缺乏病毒(HIV)感染。甲地孕 酮乙酸酯之劑量雖經報導,但未述及此組成物之種類或組 成。 近年來,甲地孕酮乙酸酯偽為可供治療用之Η劑形態 。以上提及之先前技藝顯然未説明除Μ劑或膠囊以外之甲 地孕酮乙酸酯藥學組成物。 就甲地孕酮乙酸酯在臨床藥物上的廣泛用途而言,在 病人不能呑服片劑或膠囊或高劑量需要服用相當大數量片 劑的情況下,則需要液態藥學劑型。 因此,本發明之目的在於提供甲地孕酮乙酸酯之口服 液態藥學組成物。 本發明之另一目的在於提供懸浮液形態之甲地孕酮乙 酸酯口服液態藥學組成物。 本發明之另一目的在於提供絮凝化懸浮液形態之甲地 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)T4規格(210Χ 297 Χ釐)一4 一 A6 R6 2115^0 五、發明説明(3 ) (請先閲讀背面之注意事項再塡寫本頁) 孕酮乙酸酯口服液態藥學組成物。 本發明之再一目的係為提供在産品有效期間不去絮凝 之絮凝化懸浮液形態的甲地孕酮乙酸酯藥學組成物。 本發明之再一目的係為提供在二年之至少有效期間内 保持易於分散而確保甲地孕酮乙酸酯之均勻劑量的甲地孕 _乙酸酯水分散液的口服液態劑型。 依本發明係提供甲地孕酮乙酸p旨之口服藥學組成物, 其包含徹粒化甲地孕酮乙酸酯以及聚山梨酸酯及聚乙二醇 並加入緩衝劑、甜味劑及香味以增加可口美味。 本發明之其他目的及優點將由以下説明及後面所附申 請專利範圍而顯而易見。 本發明之較理想體条包括口服藥學組成物,其包括濃 度為1 5 — 1 5〇mg/mi?之微粒化甲地孕酮乙酸酯以 及濃度為0. 005%— 0. 0 1 5%重量/體積(w/ 經濟部中央標準扃員工消費合作杜印繫 v)聚山梨酸酯及濃度大於5% w/v聚乙二醇,此組 成物形成水中之穩定絮凝化懸浮液。本發明之理想體条提 供口服藥學組成物,其包含濃度為15—15〇mg/ m又微粒化甲地孕酮乙酸酯,宜為20—120mg/ mi?,尤宜為 40mg/m)2。 懸浮液是一種待殊的分散液,其具有由基本上不溶於 ,但澈底均勻分散於懸浮介質或載體組成之外層中的粒狀 物質組成的内(懸浮)層。在本發明之最理想組成物中, 内層包含塊體平均直徑介於3和10微米之間的微粒化甲 地孕酮乙酸酯;而外層基本上像由純化水加上聚山梨酸酯 本紙張又度適用中國國家標卒(CNS)甲4规格(210 X 297公货)一5 - A6 B6 211520 五、發明説明(4 ) (請先閲讀背面之注意事項再填寫本頁) 80,聚乙二醇1450,黃蓍膠,苯酸鈉,檸檬酸,樓 樣酸鈉,蔗糖及香料。 絮凝化懸浮液具有粒狀物質之鬆散附聚物(絮片), 其中,各別粒子係以網狀結構固定在一起。絮片(稱之為 a穩定之絮片"通常包含不同數量之夾帶液態介質或載體 於網狀結構且易於叢集在一起而成弱附聚物。絮凝化懸浮 液在靜置下並不結成塊狀且易由搖動分散。絮凝化懸浮液 之組成物通常需要界面活性劑、濕化劑、保護性膠粒/懸 浮劑以産生穩定之絮片,其將阻抗去絮凝或附聚而致可能 結成塊狀。亦使用防腐劑、緩衝劑、甜味劑及香料。賦形 劑之選擇是重要的,因為相當小的變化可影響穩定絮凝化 懸浮液組成物之性質。 甲地孕酮乙酸酯(一種不濕性固體)不輕易被水潤濕 且具有經吸附於粒子表面上之夾帶空氣所加強之相當高表 面内張力。因此,必需使用界面活性劑及潤濕劑以産生懸 浮液並維持物理穩定性。 經濟部中央標準局員工消費合作社印髮 本發明之甲地孕酮乙酸酯之絮凝化懸浮液必需甲地學 酮被微粒化以令9 ◦重量%粒子小於2 0微米及塊體平均 直徑介於3 . 0和1 ◦徹米之間,而微粒化粒子以界面活 性劑或潤濕劑(諸如,聚山梨酸酯8 0及聚乙二醇 145◦,其用以減低粒子,夾帶氣體與水之間的表面内 張力)分散於水中。界面活性劑或潤濕劑之數量在提供穩 定絮Η方面是最為重要的。根據R. A. Nash, Chap. 5, 181頁,Pharmaceutica1 Suspensions, Pharmaceutical 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐)一6 — Λ6 B6 2ΐ1δ^〇 五、發明説明(5 )
Dosage Forms, Marcel Decher· New York,界面活性劑之 一般濃度偽為0. 05—0· 5% w/v且依懸浮液所 需之固態含量而定。前述懸浮液之實例示於表1中,其列 出目前市面上出售之類固醇懸浮液(1989 Physicians D_ esk Refeunce, 43販)及聚山梨酸酯8 0界面活性劑濃度 Ο 表1 依照 Physician’s Desk Reference, 43販, 在類固醇懸浮液中所用之聚山梨酸酯8 ◦濃 度之百分比__ 類固醇 類固醇濃度聚山梨酸酯80百分比
Aristocort Forte 40 0 • 2 Art i stospan 20 0 .4 5 0 .2 可的松乙酸酯 25 to 50 0 .4 Decadron~LA 8 0 .075 Depo-Provera 100 0 .184 Hydeltra-T-B.A* 20 0 .1 氫化可的松乙酸酯 25 to 50 0 .4 Kena 1 og-40 40 0 .04 在以上所示聚山梨酸酯濃度下製成之甲地孕酮乙酸酯 懸浮液在去絮凝方面並不穩定而結成塊狀。 為了獲致立即穩定之絮凝化甲地孕酮乙酸酯懸浮液, (請先閲讀背面之注意事項再項寫本頁) 丨裝· 丨‘訂. 經濟部中央標準局貝工消费合作社印製 本紙張尺度週用中國國家桴爭(CNS)甲4規恪(210 X 297 iC釐)_ 7 — A6 2115^0 B6 五、發明説明(6 ) {猜先Μ請背面之注意事項再!?寫本頁) 聚山梨酸酯濃度必需為約〇. 02% w/v或更低,宜 為◦. 005%—0· 015% w/v且尤以0. 01 % w/v為宜。當聚山梨酸酯80濃度低如 0.025% w/v時,則顯著地去絮凝並結成塊狀。 ¢0. 005-0. 01% w/v或以下之聚山梨酸酯 濃度下得到物理穩定性産物且因在這些濃度下,微粒化甲 地孕酮乙酸酯之潤濕而增加困難。亦可使用性質類似聚山 梨酸酯80之界面活性劑。在此一方面,聚山梨酸酯80 具有可為人接受之潤濕性質。可使用之其他界面活性劑係 為聚山梨酸酯20、 40、 6◦和65。 徹粒化甲地孕_乙酸酯之可潤濕性及可懸浮性係由使 用吸濕性聚合物而增強。在此一方面,宜供本發明之甲地 孕酮乙酸酯懸浮組成物用之吸濕性聚合物偽濃度為5— 經濟部中央標準局員工消費合作社印製 3 0 96 w/v,宜為 12 — 24w/v,更宜為 20% w/v 之聚乙二醇(PEG) 1450。30% w/ v PEG 1450濃度因懸浮液粘度較高而産生某些處 理上的問題,但亦提供具有可為人接受之物理性理的懸浮 液。用小於8 % P E G 1 4 5 0製得之懸浮液需要額外 費力以潤濕此藥物且據發現因為乾燥狀態之藥物(其包含 夾帶空氣而後絮凝於液體表面上)的小殘餘百分比而不合 宜。3% w/ v濃度下之聚乙二醇3 3 5 0在製造完全 濕化懸浮液方面較PEG 1450之效果差。其他级之 PEG可於較理想濃度下使用,其包括平均分子量為約 400 —4000之PEG。因為分子量較高而産生高粘 本紙張尺度通用中國國家標爭(CNS)甲4規格(210 X 297公釐)一8 — 五、發明説明(11) A6 B6 表4 如始窩麼之沈隆髙度百分比 PS 80濃度百分比 時間(週數) w/V 0 4 15 0.005 100 91 68 0.01 100 90 70 0.02 100 94 25 0.03 100 91 29 由上表顯見在0 . 0 0 5 w / V 及 0 . 0 1 w / V之 S 8 0濃度下的甲地孕酮乙酸酯懸浮液之相對絮凝程度 際上優於在0 . 0 2 w / V 或更大濃度下之P S 8 〇所 / 6之注意事項再塥寫本頁) .裝· 經濟部中央標準局貝工消費合作社印製 見及之程度。 實例4 : P EG 1 45 ◦之懸浮液穩定性: 實例1之組成物中的PEG 1 450濃度在5 — 20 % w/ v間變化。測定在時間間隔内之沈降高度並示於 表5中。
.I 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐)_ J3 _ 21152- 211520 A6 B6 五、發明説明(12) 表5 初始髙度之沈隆高度百分I:卜, PS 1450濃度百分比 時間(週數) w/v 0 4 15 20 100 77 52 15 100 85 57 10 100 本 59 8 100 木 59 6 100 拿 % 5 100 % % (請先閲讀背面之注意事項再填寫本頁) -—裝. 經濟部中央標準局W工消費合作杜印製 米由沈降粒子及其間具有澄清液中之頂層粒子示出粒子和 夾帶空氣之潤濕性差且 由此顯見PEG 1450之下限傜介於實例1組成物 之以上變化中的10至15% w/v之間。 實例5 : 聚山梨酸酯8 0之懸浮穩定性 PS8◦之濃度係在實例1組成物之0. 005— 0.025% w/v之間變化且未加入懸浮液、黃蓍膠 。測定在時間間隔内之沈降高度並示於表6中。 訂. .崠 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐)一 14·-
Claims (1)
- 2U5L0 Λ. Α7 Β7 C7 D7 經濟部中央標準局Λ工消费合作杜印製 六、申請專利範園 附件二Α : 第81104618號專利申請案 中文申請專利範圍修正本 民 1 · 一種口服藥學組成物,其包含濃 1 50mg/mJ?之微粒化甲地孕酮乙酸 0· 005%—0. 015%重量/體積 濃度大於5 96 重量/體積之聚乙二醇, 穩定絮凝化懸浮液。 2. 如申請專利範圍第1項之組成物 甲地孕酮乙酸酯之濃度是為20—120 3. 如申請專利範圍第1項之組成物 甲地孕酮乙酸酯之濃度為4 0m g /m又 4 .如申請專利範圍第1項之組成物 山梨酸酯8 0。 5.如申請專利範圍第1項之組成物 醇之濃度係為5%— 3 0%重量/體積。 6 .如申請專利範圍第1項之組成物 醇之濃度係為12—24%重量/體積。 7. 如申請專利範圍第1項之組成物 醇之濃度係為2 0%重量/體積。 8. 如申請專利範圍第1項之組成物 酸酯之濃度偽為〇. 01%重量/體積。 9. 如申請專利範圍第1項之組成物 國81年12月修正 度為1 5 — 酯以及濃度為 之聚山梨酸酯與 其形成在水中之 ,其中,微粒化 m g / m 〇 ,其中,微粒化 0 ,其中係採用聚 ,其中,聚乙二 ,其中,聚乙二 ,其中,聚乙二 ,其中,聚山梨 ,其包含緩衝劑 (請先閲讀背面之注意事項再璜寫本頁) •裝_ 訂. L纸張尺茂適用中國阀家標準(CNS)甲4規格(210 X 297公釐) 1 81.9.10,000 A7 产 B7 C7 D7 六、申請專利範困 、甜味劑及香料。 10.—種口服藥學組成物,其包含以重量/體積百 分比為基準之4% 甲地孕酮乙酸酯,20% 聚乙二醇 1450, ◦. 01%聚山梨酸酯80, 0. 2%黃蓍膠 ,0. 2%苯甲酸鈉,〇. 244%檸檬酸,〇.15% 檸檬酸鈉,5%蔗糖,0. 091%檸檬一萊姆香料,而 其餘為純化水,此組成物形成水中之穩定絮凝化懸浮液。 (請先閲讀背面之注意事項再璜寫本页) -裝. -·訂. 經濟部中央標準房8X消费合作杜印製 本紙張尺度適用中國囤家標準(CNS) ψ4规格(21〇Χ 297公釐) -2 - 81.9.10,000
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71715591A | 1991-06-18 | 1991-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW211520B true TW211520B (zh) | 1993-08-21 |
Family
ID=24880926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW081104618A TW211520B (zh) | 1991-06-18 | 1992-06-12 |
Country Status (22)
Country | Link |
---|---|
US (1) | US5338732A (zh) |
EP (1) | EP0519351B1 (zh) |
JP (1) | JP3450356B2 (zh) |
KR (1) | KR100211192B1 (zh) |
CN (1) | CN1038904C (zh) |
AT (1) | ATE142882T1 (zh) |
AU (1) | AU647933B2 (zh) |
CA (1) | CA2071141A1 (zh) |
CZ (1) | CZ289620B6 (zh) |
DE (1) | DE69213836T2 (zh) |
DK (1) | DK0519351T3 (zh) |
ES (1) | ES2091977T3 (zh) |
FI (1) | FI101602B (zh) |
GR (1) | GR3021072T3 (zh) |
HK (1) | HK1005017A1 (zh) |
HU (1) | HU213511B (zh) |
IE (1) | IE77167B1 (zh) |
IL (1) | IL102198A (zh) |
MX (1) | MX9202944A (zh) |
SK (1) | SK281841B6 (zh) |
TW (1) | TW211520B (zh) |
ZA (1) | ZA924282B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI807234B (zh) * | 2020-02-20 | 2023-07-01 | 大陸商東曜藥業有限公司 | 一種口服醋酸甲地孕酮懸濁液及其製備方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698562A (en) * | 1991-10-08 | 1997-12-16 | Ascent Pediatrics, Inc. | Palatable trimethoprim oral solution |
US5563177A (en) * | 1995-01-30 | 1996-10-08 | American Home Products Corporation | Taste masking guaifenesin containing liquids |
US6028065A (en) * | 1998-04-20 | 2000-02-22 | Pharmaceutical Resources, Inc. | Flocculated suspension of megestrol acetate |
US6268356B1 (en) | 1998-04-20 | 2001-07-31 | Pharmaceutical Resources, Inc. | Flocculated suspension of megestrol acetate |
US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
US20030198679A1 (en) * | 2000-11-08 | 2003-10-23 | Kundu Subhas C. | Flocculated pharmaceutical suspensions and methods for actives |
EP1275377B1 (en) * | 2001-07-11 | 2003-06-18 | Apr Applied Pharma Research S.A. | Granulates containing liposoluble substances and process of preparation thereof |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
AU2003230885A1 (en) * | 2002-04-12 | 2003-10-27 | Elan Pharma International Ltd. | Nanoparticulate megestrol formulations |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
DE10224086A1 (de) * | 2002-05-31 | 2003-12-11 | Bayer Ag | Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker |
KR100841082B1 (ko) | 2006-08-23 | 2008-06-24 | 대원제약주식회사 | 메게스트롤 아세테이트의 서상화된 현탁제 |
KR20080035374A (ko) * | 2006-10-19 | 2008-04-23 | 주식회사 엘지생명과학 | 약제학적으로 안정한 메게스트롤 물질의 현탁액제 |
CN101678112B (zh) * | 2007-01-19 | 2016-08-31 | 哈南亚有限公司 | 用于递送治疗剂的方法和组合物 |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
WO2008089549A1 (en) | 2007-01-22 | 2008-07-31 | Genpharm Ulc | Pharmaceutical compositions comprising nebivolol or a nebivolol analogue |
TW201023912A (en) * | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
WO2010101989A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
KR101279568B1 (ko) * | 2010-12-10 | 2013-07-15 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | 메게스트롤 아세테이트를 포함하는 경구용 약학 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB870286A (en) * | 1958-11-04 | 1961-06-14 | British Drug Houses Ltd | Improvements in or relating to 6-methyl-3-oxo-í~-steroid compounds |
FR2290906A1 (fr) * | 1974-11-13 | 1976-06-11 | Dick Pierre | Nouvelles associations hormonales synergisees pour l'implantation d'animaux de boucherie |
US4370321A (en) * | 1976-09-01 | 1983-01-25 | Mead Johnson And Company | Progestational adjuvant therapy |
JPS5522631A (en) * | 1978-08-07 | 1980-02-18 | Ota Seiyaku Kk | Readily absorbable nifedipine preparation |
US4402695A (en) * | 1980-01-21 | 1983-09-06 | Alza Corporation | Device for delivering agent in vagina |
US4396615A (en) * | 1981-06-24 | 1983-08-02 | Duke University | Method of treating androgen-related disorders |
US4666885A (en) * | 1985-02-08 | 1987-05-19 | Fernand Labrie | Combination therapy for treatment of female breast cancer |
US4760053A (en) * | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
US4782047A (en) * | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
-
1992
- 1992-05-13 US US07/882,218 patent/US5338732A/en not_active Expired - Lifetime
- 1992-06-11 ZA ZA924282A patent/ZA924282B/xx unknown
- 1992-06-12 TW TW081104618A patent/TW211520B/zh not_active IP Right Cessation
- 1992-06-12 AT AT92109946T patent/ATE142882T1/de not_active IP Right Cessation
- 1992-06-12 DK DK92109946.1T patent/DK0519351T3/da active
- 1992-06-12 DE DE69213836T patent/DE69213836T2/de not_active Expired - Fee Related
- 1992-06-12 ES ES92109946T patent/ES2091977T3/es not_active Expired - Lifetime
- 1992-06-12 CA CA002071141A patent/CA2071141A1/en not_active Abandoned
- 1992-06-12 EP EP92109946A patent/EP0519351B1/en not_active Expired - Lifetime
- 1992-06-15 IL IL10219892A patent/IL102198A/en not_active IP Right Cessation
- 1992-06-15 FI FI922764A patent/FI101602B/fi active
- 1992-06-15 KR KR1019920010328A patent/KR100211192B1/ko not_active IP Right Cessation
- 1992-06-16 SK SK1853-92A patent/SK281841B6/sk not_active IP Right Cessation
- 1992-06-16 CZ CS19921853A patent/CZ289620B6/cs not_active IP Right Cessation
- 1992-06-17 MX MX9202944A patent/MX9202944A/es unknown
- 1992-06-17 JP JP19889292A patent/JP3450356B2/ja not_active Expired - Lifetime
- 1992-06-17 HU HU9202029A patent/HU213511B/hu unknown
- 1992-06-17 CN CN92104762A patent/CN1038904C/zh not_active Expired - Fee Related
- 1992-06-17 AU AU18281/92A patent/AU647933B2/en not_active Expired
- 1992-07-01 IE IE921958A patent/IE77167B1/en not_active IP Right Cessation
-
1996
- 1996-09-19 GR GR960400478T patent/GR3021072T3/el unknown
-
1998
- 1998-05-15 HK HK98104209A patent/HK1005017A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI807234B (zh) * | 2020-02-20 | 2023-07-01 | 大陸商東曜藥業有限公司 | 一種口服醋酸甲地孕酮懸濁液及其製備方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW211520B (zh) | ||
US20200114011A1 (en) | Aqueous drug delivery system | |
US5658919A (en) | Aqueous pharmaceutical suspension and process for preparation thereof | |
US4721709A (en) | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions | |
US20030191192A1 (en) | Oral suspension formulation | |
US6268356B1 (en) | Flocculated suspension of megestrol acetate | |
US6028065A (en) | Flocculated suspension of megestrol acetate | |
US20020028794A1 (en) | Megestrol acetate suspension | |
US3347744A (en) | Magnesium hydroxide suspensions | |
JP2922456B2 (ja) | トリメブチンを含む新規医薬組成物及びその調製法 | |
CN117883379A (zh) | 一种口服碱性溶媒组合物及其制备方法与应用 | |
JPH0696536B2 (ja) | 制酸剤含有内用懸濁液 | |
KR100841082B1 (ko) | 메게스트롤 아세테이트의 서상화된 현탁제 | |
JP2003104881A (ja) | 内服用懸濁液剤 | |
TW536409B (en) | Drinkable pharmaceutical composition | |
US20040198634A1 (en) | Flocculated pharmaceutical suspensions and methods for actives | |
CN114099443A (zh) | 一种奥司他韦药物组合物及其制备方法和用途 | |
HU211660A9 (hu) | Megestrol-acetátot tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |